Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Ciaran McCrickard)
September 24, 2021 11:02 AM EDTUpdated 01:35 PM
FDA+

New ARIA cas­es dog Bio­gen's Aduhelm launch in an­oth­er po­ten­tial blow to block­buster hopes — an­a­lyst

Kyle Blankenship

Per­haps an­tic­i­pat­ing a walkover with an FDA ap­proval in hand, Bio­gen has in­stead faced a wall of push­back over its con­tro­ver­sial Alzheimer’s med Aduhelm …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times